Adam Feuerstein

Before joining TheStreet in March 2001, Feuerstein covered business software for Upside.com. Prior to that he covered a variety of business beats, including technology and commercial real estate, at the San Francisco Business Times.

 


Feuerstein graduated from Emory University with a bachelor's degree in political science.

 


Recent Articles By The Author

Why Gilead Can't Easily Copy Celgene's 'Partner Partner Partner' Deal-Making Playbook

Why Gilead Can't Easily Copy Celgene's 'Partner Partner Partner' Deal-Making Playbook

When your top line declines, it's harder to convince investors it's okay to wait years see if a partnership in an early-stage biotech company delivers a home-run drug.

Celgene Can't Expand Revlimid Approval Into Non-Hodgkin Lymphoma Just Yet

Celgene Can't Expand Revlimid Approval Into Non-Hodgkin Lymphoma Just Yet

Celgene will not seek approval for Revlimid as a maintenance therapy for patients with diffuse large B-cell lymphoma based on the lack of a survival benefit in a clinical trial.

Gilead Lowers Product Sales Guidance on Weak Hepatitis C Sales

Gilead Lowers Product Sales Guidance on Weak Hepatitis C Sales

Gilead's stock trades at a discount to other biotech peers because its drug research pipeline lacks the blockbusters needed to make up for slowing sales from its hepatitis C franchise.

PTC Therapeutics Duchenne Drug Stuck on Conditional Approval Status in Europe

PTC Therapeutics Duchenne Drug Stuck on Conditional Approval Status in Europe

European regulators have delayed PTC Therapeutics' request for permanent approval of its Duchenne muscular dystrophy drug Translarna.

Biogen CEO Resigns After Six Years of Boom-and-Bust Leadership

Biogen CEO Resigns After Six Years of Boom-and-Bust Leadership

The departure of Biogen's CEO could lead to a sale of the biotech company, or a renewed push to boost its own M&A activities.